💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sitaxentan Sodium

CHEMBL2105740 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
476.9 g/mol
LogP
—
Phase
4

Sitaxentan sodium is the sodium salt form of sitaxentan, a selective ETA receptor antagonist that was developed for pulmonary arterial hypertension but withdrawn due to hepatotoxicity concerns. See sitaxentan for complete pharmacological details.

Khối lượng phân tử

476,9000 g/mol

TPSA

133,00 Ų

Lĩnh vực điều trị

Chronic Kidney Disease Hypertension Heart Failure

Cơ chế tác dụng

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+]

                

                

                
                

                    
InChI

                    
InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H14ClN2NaO6S2

                    

                    
                    

                        
HBD / HBA

                        
- / 9

                    

                    
                    

                        
Liên kết có thể quay

                        
6

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
Sitaxentan sodium is the sodium salt form of sitaxentan, a selective ETA receptor antagonist that was developed for pulmonary arterial hypertension but withdrawn due to hepatotoxicity concerns. See sitaxentan for complete pharmacological details.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Sitaxentan Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105740.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11477084.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.